BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22515612)

  • 1. Pharmacogenetics of aromatase inhibitors.
    Hadfield KD; Newman WG
    Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
    Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
    Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
    Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.
    Rumiato E; Brunello A; Ahcene-Djaballah S; Borgato L; Gusella M; Menon D; Pasini F; Amadori A; Saggioro D; Zagonel V
    Pharmacogenomics J; 2016 Nov; 16(6):525-529. PubMed ID: 26503812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
    Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
    Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
    Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
    Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
    Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenomics of third-generation aromatase inhibitors.
    Turkistani A; Marsh S
    Expert Opin Pharmacother; 2012 Jun; 13(9):1299-307. PubMed ID: 22594760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
    Miron L; Negură L; Peptanariu D; Marinca M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of bone disease in patients undergoing hormonal therapy for breast cancer.
    Mirza FS
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):549-62, viii. PubMed ID: 21889720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of endocrine therapies for breast cancer: where are we headed?
    Arnedos M; Smith I
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1651-64. PubMed ID: 18020931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent topics in endocrine therapy for hormone-dependent breast cancer: basic research and clinical applications.
    Kimijima I
    Breast Cancer; 2008; 15(4):253-5. PubMed ID: 18953680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.